This is a preview of subscription content, log in via an institution to check access.
Notes
The analysis and article processing charges were funded by Janssen Global Services, LLC.
Reference
Neslusan C, et al. Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States. Diabetes Therapy 9: 565-581, No. 2, Apr 2018. Available from: URL: http://doi.org/10.1007/s13300-018-0371-y
Rights and permissions
About this article
Cite this article
Canagliflozin in T2DM: better outcomes, lower cost. PharmacoEcon Outcomes News 801, 4 (2018). https://doi.org/10.1007/s40274-018-4859-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4859-5